HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 278, Issue 3, 1433-1442, January 17, 2003

This Article Full Text Full Text (PDF) All Versions of this Article: 278/3/1433    most recent M208297200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bai, J. Articles by Marasco, W. A. Search for Related Content PubMed PubMed Citation Articles by Bai, J. Articles by Marasco, W. A. Social Bookmarking                      What's this?

Inhibition of Tat-mediated Transactivation and HIV-1 Replication by Human Anti-hCyclinT1 Intrabodies^*

Jirong Bai, Jianhua Sui^§, Rui Ying Zhu, Aimée St. Clair Tallarico, Francesca Gennari^§, Dongsheng Zhang^§, and Wayne A. Marasco^§¶

From the  Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute and ^§ Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115

Human immunodeficiency virus, type 1 (HIV-1) replication requires the interaction of Tat protein with the human cyclinT1 (hCyclinT1) subunit of the positive transcription elongation factor (P-TEFb) complex, which then cooperatively binds to transactivation response element (TAR) RNA to transactivate HIV transcription. In this report, a non-immune human single-chain antibody (sFv) phage display library was used to isolate anti-hCyclinT1 sFvs that could disrupt hCyclinT1-Tat interactions. The N-terminal 272 residues of hCyclinT1, including the entire cyclin domains and the Tat·TAR recognition motif (TRM), that fully support Tat transactivation was used for panning, and of the five unique anti-hCyclinT1 sFvs that were obtained, three bound to the cyclin box domains and two bound to TRM. All sFvs could be expressed as intrabodies at high levels in transiently transfected 293T and in stable Jurkat and SupT1 transfectants and could specifically co-immunoprecipitate co-expressed hCyclinT1 in 293T cells with varying efficacy without disrupting hCyclinT1-Cdk9 interactions. In addition, two sFv clones (3R6-1 and 2R6-21) that mapped to the cyclin box domains markedly inhibited Tat-mediated transactivation in several transiently transfected cell lines without inhibiting basal transcription or inducing apoptosis. When HIV-1 challenge studies were performed on stable 3R6-1-expressing Jurkat T cells, near complete inhibition of viral replication was obtained at a low challenge dose, and 74-88% inhibition to HIV-1 replication was achieved at a high infection dose in SupT1 cells. These results provide proof-in-principle that anti-hCyclinT1 intrabodies can be designed to block HIV-1 replication without causing cellular toxicity, and as a result, they may be useful agents for "intracellular immunization"-based gene therapy strategies for HIV-1 infection/AIDS.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. K. Jadlowsky, M. Nojima, T. Okamoto, and K. Fujinaga Dominant negative mutant cyclin T1 proteins that inhibit HIV transcription by forming a kinase inactive complex with Tat J. Gen. Virol., November 1, 2008; 89(11): 2783 - 2787. [Abstract] [Full Text] [PDF]

				C. Xu, J. Sui, H. Tao, Q. Zhu, and W. A. Marasco Human Anti-CXCR4 Antibodies Undergo VH Replacement, Exhibit Functional V-Region Sulfation, and Define CXCR4 Antigenic Heterogeneity J. Immunol., August 15, 2007; 179(4): 2408 - 2418. [Abstract] [Full Text] [PDF]

				L. H. Gould, J. Sui, H. Foellmer, T. Oliphant, T. Wang, M. Ledizet, A. Murakami, K. Noonan, C. Lambeth, K. Kar, et al. Protective and Therapeutic Capacity of Human Single-Chain Fv-Fc Fusion Proteins against West Nile Virus J. Virol., December 1, 2005; 79(23): 14606 - 14613. [Abstract] [Full Text] [PDF]

				K. Paz, L. A. Brennan, M. Iacolina, J. Doody, Y. R. Hadari, and Z. Zhu Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation Mol. Cancer Ther., November 1, 2005; 4(11): 1801 - 1809. [Abstract] [Full Text] [PDF]

				Y.-L. Chiu, H. Cao, J.-M. Jacque, M. Stevenson, and T. M. Rana Inhibition of Human Immunodeficiency Virus Type 1 Replication by RNA Interference Directed against Human Transcription Elongation Factor P-TEFb (CDK9/CyclinT1) J. Virol., March 1, 2004; 78(5): 2517 - 2529. [Abstract] [Full Text] [PDF]

				J. Sui, W. Li, A. Murakami, A. Tamin, L. J. Matthews, S. K. Wong, M. J. Moore, A. St. C. Tallarico, M. Olurinde, H. Choe, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association PNAS, February 24, 2004; 101(8): 2536 - 2541. [Abstract] [Full Text] [PDF]

				N. Jendreyko, M. Popkov, R. R. Beerli, J. Chung, D. B. McGavern, C. Rader, and C. F. Barbas III Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors J. Biol. Chem., November 28, 2003; 278(48): 47812 - 47819. [Abstract] [Full Text] [PDF]